Assessment of Response to Immunotherapy in Patients with Hodgkin Lymphoma: Towards Quantifying Changes in Tumor Burden Using FDG-PET/CT

Immune checkpoint inhibitors are currently the standard of care for many advanced solid tumors, and they have been recently approved for the treatment of relapsed/refractory Hodgkin lymphoma and primary mediastinal B cell lymphoma. Assessments of the response to immunotherapy may be complicated by t...

Descripción completa

Detalles Bibliográficos
Autores principales: Tutino, Francesca, Giovannini, Elisabetta, Chiola, Silvia, Giovacchini, Giampiero, Ciarmiello, Andrea
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10219254/
https://www.ncbi.nlm.nih.gov/pubmed/37240602
http://dx.doi.org/10.3390/jcm12103498

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10219254/
https://www.ncbi.nlm.nih.gov/pubmed/37240602
http://dx.doi.org/10.3390/jcm12103498

Ejemplares similares